Table 1.
1999-2000 | 2001-2002 | 2003-2004 | 2005-2006 | 2007-2008 | 2009-2010 | P for trendb | Total | P for between-group comparisonc | |
---|---|---|---|---|---|---|---|---|---|
Statin-Users | |||||||||
| |||||||||
Unweighted sample, N | 374 | 537 | 652 | 717 | 1,105 | 1,158 | |||
| |||||||||
Weighted proportion of statin-users, % | 7.5 | 9.2 | 11.1 | 13.5 | 15.4 | 16.5 | <.001 | ||
| |||||||||
Age Ranged, y, % | |||||||||
20–39 | 0.7 | 3.8 | 1.9 | 2.6 | 3.8 | 2.5 | .31 | 2.7 | <.001 |
40–59 | 39.8 | 39.5 | 39.6 | 34.8 | 31.9 | 36.8 | .04 | 36.4 | <.001 |
60– | 59.6 | 56.7 | 58.5 | 62.7 | 64.3 | 60.7 | .10 | 60.9 | <.001 |
Female sex, % | 47.8 | 45.5 | 47.5 | 49.0 | 48.5 | 45.8 | .89 | 47.4 | <.001 |
Racial and ethnicityd, % | |||||||||
Non-Hispanic white | 83.8 | 86.1 | 83.3 | 80.1 | 79.9 | 78.2 | .03 | 81.1 | <.001 |
Non-Hispanic black | 4.9 | 6.1 | 7.4 | 10.0 | 8.7 | 9.2 | .02 | 8.2 | <.001 |
Mexican American | 2.0 | 2.1 | 3.1 | 2.8 | 4.2 | 4.8 | .12 | 3.5 | <.001 |
Otherse | 9.3 | 5.7 | 6.2 | 7.1 | 7.3 | 7.8 | .81 | 7.2 | <.001 |
Educational attainment, % | |||||||||
> High school | 41.6 | 53.0 | 45.3 | 50.2 | 48.9 | 55.2 | .03 | 49.9 | <.001 |
High school or GEDf | 31.5 | 27.1 | 33.6 | 30.7 | 29.9 | 24.2 | .07 | 29.1 | .002 |
< High school | 26.9 | 19.9 | 21.1 | 19.1 | 21.2 | 20.6 | .28 | 21.0 | .04 |
Diabetes diagnosis, % | 21.5 | 23.9 | 27.7 | 29.7 | 29.8 | 29.3 | .009 | 27.9 | <.001 |
Total cholesterol level, mean (SD), mg/dL | 201.9 (32.1) | 195.8 (35.7) | 191.1 (37.6) | 183.0 (35.1) | 177.2 (36.5) | 178.1 (33.7) | <.001 | 185.1 (36.3) | <.001 |
LDL-Cg level, mean (SD), mg/dL | 119.3 (32.1) | 112.4 (27.7) | 100.6 (27.6) | 96.7 (30.4) | 96.4 (31.6) | 99.8 (28.7) | <.001 | 101.8 (30.5) | <.001 |
Body mass index, mean (SD), kg/m2 | 29.2 (4.6) | 29.5 (5.3) | 29.7 (5.2) | 30.5 (5.4) | 30.4 (6.3) | 30.5 (6.0) | <.001 | 30.1 (5.7) | <.001 |
| |||||||||
Statin Non-users | |||||||||
| |||||||||
Unweighted sample, N | 4,220 | 4,552 | 4,154 | 3,926 | 4,768 | 4,991 | |||
| |||||||||
Age Range, y, % | |||||||||
20–39 | 43.5 | 40.7 | 42.4 | 42.1 | 43.1 | 43.0 | .59 | 42.4 | - |
40–59 | 35.5 | 40.8 | 39.0 | 40.6 | 40.4 | 39.1 | .02 | 39.3 | - |
60– | 21.0 | 18.5 | 18.6 | 17.3 | 16.5 | 17.9 | .005 | 18.3 | - |
Female sex, % | 51.3 | 52.0 | 51.8 | 51.2 | 51.9 | 52.3 | .53 | 51.8 | - |
Racial and ethnicityd, % | - | ||||||||
Non-Hispanic white | 68.7 | 70.9 | 70.6 | 70.9 | 67.9 | 66.1 | .39 | 69.2 | - |
Non-Hispanic black | 11.2 | 11.1 | 11.6 | 11.7 | 11.7 | 11.8 | .69 | 11.5 | - |
Mexican American | 7.6 | 7.2 | 8.2 | 8.5 | 9.0 | 9.2 | .33 | 8.3 | - |
Otherse | 12.6 | 10.9 | 9.6 | 9.0 | 11.4 | 12.9 | .88 | 11.1 | - |
Educational attainmentd, % | - | ||||||||
> High school | 49.4 | 55.3 | 55.7 | 58.4 | 54.9 | 58.7 | .007 | 55.4 | - |
High school or GEDf | 25.5 | 25.3 | 26.3 | 24.2 | 24.6 | 22.7 | .14 | 24.8 | - |
< High school | 25.1 | 19.5 | 18.0 | 17.4 | 20.5 | 18.7 | .003 | 19.8 | - |
Diabetes diagnosis, % | 5.5 | 5.5 | 5.8 | 4.8 | 5.7 | 5.1 | .56 | 5.4 | - |
Diagnosed with hyperlipidemia, % | 19.3 | 18.5 | 22.0 | 21.6 | 21.7 | 18.8 | .30 | 20.3 | - |
Total cholesterol level, mean (SD), mg/dL | 203.6 (32.3) | 203.1 (35.0) | 202.9 (33.5) | 201.1 (31.3) | 200.9 (34.2) | 199.6 (36.1) | .002 | 201.8 (33.8) | - |
LDL-Cg level, mean (SD), mg/dL | 126.2 (30.3) | 121.7 (30.0) | 118.9 (28.7) | 118.0 (27.9) | 119.5 (30.3) | 119.8 (32.7) | <.001 | 120.6 (30.1) | - |
Body mass index, mean (SD), kg/m2 | 27.9 (5.1) | 27.9 (5.0) | 28.0 (5.0) | 28.2 (5.2) | 28.2 (5.6) | 28.4 (5.8) | .02 | 28.1 (5.3) | - |
Sample size varies for certain characteristics. Each analysis accounted for an appropriate sample weight and the complex study design.
Trends over time were assessed using chi-squared tests for linear trends for categorical variables and linear regressions for continuous variables.
Comparisons between statin-users and non-users were made using pooled samples across the study period.
Percentages do not sum to 100% due to rounding.
The category includes other Hispanics and other races including multi-racial participants.
General Education Development.
Low-density lipoprotein cholesterol.